Table 3.

Not yet licensed oral cholera vaccines under development.

Type of Vaccine	Name/Description/Stage of Development
Simplified compositions of current OCVs	Formalin-killed Cairo 50 (Classical/Ogawa) and Phil6973 (El Tor/Inaba), which is in preclinical development in South Korea. Hillchol™, which contains formalin-killed Hikojima El Tor strain MS1568 and is developed in India and Sweden. This OCV is in planned phase 3 testing in India. Formalin-killed co-cultured isogenic El Tor Ogawa and Inaba, which is in preclinical development in Sweden.
Thermostable dry formulation capsule OCV	DuoChol™, which contains lyophilized formalin-killed isogenic El Tor Ogawa and Inaba strains and recombinant cholera toxin B subunit in an enteroprotected capsule. This OCV is in preclinical development in Sweden.
Live attenuated OCVs	Genetically engineered V. cholerae O1 strains with deletions of ctx and other mutations: Peru 15, which is derived from an O1 El Tor Inaba clinical isolate from 1991 in Peru, and is developed in the USA. This OCV has displayed phase 1 (also including challenge) and phase 2 immunogenicity. El Tor Ogawa strain 638, which is developed in Cuba. This OCV has displayed phase 1 (also including challenge) and phase 2 immunogenicity. VA 1.4 El Tor Inaba strain, which is developed in India. This OCV has displayed phase 1 immunogenicity. IEM 108 El Tor Ogawa strain, which is developed in China. This OCV has displayed phase 1 immunogenicity. HaitiV, which is derived from a variant El Tor O1 Ogawa isolated in Haiti, and is in preclinical development in the USA.